MDR1启动子调控的双自杀基因真核表达载体的构建及其在K562/A02细胞中的表达  

Construction of expressive vector containing double suicide genes controlled by MDR1 promoter and its expression in K562/A02 cell

作　　者：王向玲[1] 纪春岩[1] 马道新[1] 赵建强[1] 侯明[1] 余海青[1] 臧绍蕾[1] 

机构地区：[1]山东大学齐鲁医院血液学研究室,山东济南250012

出　　处：《山东大学学报（医学版）》2006年第4期336-340,共5页Journal of Shandong University:Health Sciences

基　　金：国家自然科学基金资助课题(30471941);山东省科技发展计划(031050104);山东省科技发展计划资助课题(2002BB1CJA3)

摘　　要：目的:构建多药耐药基因(MDR1)启动子调控的CD-TK双自杀基因真核表达载体用于耐药白血病的靶向性基因治疗。方法:采用PCR方法从K562/A02细胞基因组DNA中扩增MDR1启动子,将其连接到双自杀基因CD-TK的上游,构建pcDNA3-MDR1-Promoter-CD-TK真核表达载体,用脂质体介导法将构建好的载体转染入K562、K562/A02细胞,PCR鉴定CD、TK基因的整合,RT-PCR鉴定CD、TK基因的表达。结果:PCR克隆出MDR1启动子经DNA测序证实序列正确,通过连接成功构建含正确目的基因的表达载体pcDNA3-MDR1-Promoter-CD-TK。转染入细胞后PCR结果显示,CD、TK基因均整合入K562、K562/A02细胞中,RT-PCR结果显示,K562/A02/CD-TK细胞CD、TK基因有特异性条带表达,而K562/CD-TK细胞无特异性条带。结论:MDR1启动子调控的CD-TK双自杀基因真核表达载体的成功构建及其在K562/A02细胞中的特异性表达为耐药白血病的靶向性基因治疗提供了实验基础。Objective： To construct expressive vector containing double suicide genes targeted by MDR1 promoter for the purpose of targeted gene therapy for MDR leukemia. Methods： The DNA fragment of MDR1 promoter was amplified from genome DNA of K562/A02 cells with PCR and was inserted into the upstream of CD-TK to construct pcDNA3-MDR1-Promoter-CD-TK. This recombinant vector was transfected into K562, K562/A02 cells by means of liposome. PCR and RT-PCR were resorted to identify the integration and expression of CD and TK genes. Results： The length and sequence of MDR1 promoter amplified by PCR were confirmed by DNA sequencing. The pcDNA3-MDR1-Promoter-CD-TK expression vectors were constructed successfully. PCR proved double suicide genes were integrated into K562/A02 and K562 cells. RT-PCR revealed that CD and TK genes expressed in K562/A02/CD- TK cells, whereas not in K562/CD-TK ceils. Conclusion： Construction of expressive vector containing double suicide genes targeted by MDR1 promoter and its specific expression in K562/A02 cell provide a sound basis for targeted gene therapy for MDR leukemia.

关 键 词：基因 MDR 启动子 自杀基因 质粒 

分 类 号：R733.7[医药卫生—肿瘤] Q786[医药卫生—临床医学]